HRP20040016A2 - Process for the production of n-[3-[3-cyanopyrazolo [1,5-a] pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon) - Google Patents

Process for the production of n-[3-[3-cyanopyrazolo [1,5-a] pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon) Download PDF

Info

Publication number
HRP20040016A2
HRP20040016A2 HR20040016A HRP20040016A HRP20040016A2 HR P20040016 A2 HRP20040016 A2 HR P20040016A2 HR 20040016 A HR20040016 A HR 20040016A HR P20040016 A HRP20040016 A HR P20040016A HR P20040016 A2 HRP20040016 A2 HR P20040016A2
Authority
HR
Croatia
Prior art keywords
acid
zaleplon
water
reaction medium
ethylacetamide
Prior art date
Application number
HR20040016A
Other languages
English (en)
Croatian (hr)
Inventor
Erika Feher
Erika Magyar
Ferenc Korodi
Original Assignee
Biogal Gyogyszergyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogal Gyogyszergyar filed Critical Biogal Gyogyszergyar
Publication of HRP20040016A2 publication Critical patent/HRP20040016A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20040016A 2001-06-12 2002-06-12 Process for the production of n-[3-[3-cyanopyrazolo [1,5-a] pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon) HRP20040016A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29763501P 2001-06-12 2001-06-12
PCT/US2002/018567 WO2002100828A2 (en) 2001-06-12 2002-06-12 Process for the production of zaleplon

Publications (1)

Publication Number Publication Date
HRP20040016A2 true HRP20040016A2 (en) 2004-10-31

Family

ID=23147125

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040016A HRP20040016A2 (en) 2001-06-12 2002-06-12 Process for the production of n-[3-[3-cyanopyrazolo [1,5-a] pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon)

Country Status (20)

Country Link
US (2) US6884888B2 (pl)
EP (1) EP1406871A4 (pl)
JP (1) JP2005507858A (pl)
KR (1) KR20040007683A (pl)
CN (1) CN1537113A (pl)
CA (1) CA2450384A1 (pl)
CZ (1) CZ20033544A3 (pl)
DE (1) DE02778962T1 (pl)
ES (1) ES2223311T1 (pl)
HR (1) HRP20040016A2 (pl)
HU (1) HUP0402257A2 (pl)
IL (1) IL159281A0 (pl)
IS (1) IS7069A (pl)
MX (1) MXPA03011485A (pl)
NO (1) NO20035538D0 (pl)
PL (1) PL372942A1 (pl)
SK (1) SK16232003A3 (pl)
TR (1) TR200402588T3 (pl)
WO (1) WO2002100828A2 (pl)
ZA (1) ZA200309677B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032818A1 (en) * 2001-06-12 2005-02-10 Entire Interest N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide and crystalline forms of zaleplon
HRP20040016A2 (en) * 2001-06-12 2004-10-31 Biogal Gyogyszergyar Process for the production of n-[3-[3-cyanopyrazolo [1,5-a] pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon)
MXPA04001035A (es) * 2001-08-01 2004-06-22 Biogal Gyogyszergyar Proceso para purificar n-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)fenil]-n-etilacetamida (zaleplon) y formas cristalinas de zaleplon accesibles con este proceso.
ZA200406577B (en) * 2002-02-15 2006-06-28 Teva Gyogyzeryan Reszvenytarsa Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
PL207322B1 (pl) * 2002-05-14 2010-11-30 Adamed Społka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania zaleplonu
WO2004035585A1 (en) * 2002-10-16 2004-04-29 Sanmar Speciality Chemicals Limited Synthesis of zaleplon
CZ20023575A3 (cs) * 2002-10-25 2004-01-14 Léčiva, A.S. Způsob výroby N-ethyl-N-[3-(3-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-fenyl]-acetamidu (zaleplonu)
DE112004001615T5 (de) * 2003-09-04 2006-06-14 Cipla Ltd. Zaleplon-Synthese
AU2004314335A1 (en) * 2004-01-14 2005-08-04 Mallinckrodt Inc. Two-phase method for the synthesis of selected pyrazolopyrimidines
HUP0400325A3 (en) 2004-02-02 2005-11-28 Richter Gedeon Vegyeszet Pure n-[3-(-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethyl-acetamide, process for its preparation and intermediates
WO2005099712A2 (en) * 2004-04-19 2005-10-27 Sanmar Speciality Chemicals Limited Process for preparation of n-[3-(3-cyanopyrazolo [1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide
WO2006070244A2 (en) * 2004-11-22 2006-07-06 Bakulesh Mafatlal Khamar A process for the preparation of zaleplon
CN102816163A (zh) * 2012-08-20 2012-12-12 四川禾邦阳光制药股份有限公司 扎来普隆的新晶型及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626538A (en) 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en) * 1999-09-02 2002-05-07 Neurocrine Biosciences, Inc. Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
NZ527455A (en) * 2000-08-03 2005-07-29 Wyeth Corp Polymorphs of zaleplon and methods for the preparation thereof
AR029780A1 (es) * 2000-12-13 2003-07-16 Gador Sa Procedimiento mejorado para la obtencion de n-[3(3-ciano-pirazolo[1,5-a]pirimidin-7-il)fenil]-n-etil-acetamida
HRP20040016A2 (en) * 2001-06-12 2004-10-31 Biogal Gyogyszergyar Process for the production of n-[3-[3-cyanopyrazolo [1,5-a] pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon)
MXPA04001035A (es) * 2001-08-01 2004-06-22 Biogal Gyogyszergyar Proceso para purificar n-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)fenil]-n-etilacetamida (zaleplon) y formas cristalinas de zaleplon accesibles con este proceso.
PL207322B1 (pl) * 2002-05-14 2010-11-30 Adamed Społka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania zaleplonu

Also Published As

Publication number Publication date
US6884888B2 (en) 2005-04-26
WO2002100828A2 (en) 2002-12-19
EP1406871A2 (en) 2004-04-14
HUP0402257A2 (hu) 2005-02-28
ZA200309677B (en) 2004-12-13
KR20040007683A (ko) 2004-01-24
IS7069A (is) 2003-12-10
CZ20033544A3 (cs) 2004-11-10
DE02778962T1 (de) 2005-02-10
US20030040522A1 (en) 2003-02-27
JP2005507858A (ja) 2005-03-24
MXPA03011485A (es) 2004-06-11
TR200402588T3 (tr) 2004-11-22
ES2223311T1 (es) 2005-03-01
PL372942A1 (pl) 2005-08-08
CA2450384A1 (en) 2002-12-19
US20050187225A1 (en) 2005-08-25
IL159281A0 (en) 2004-06-01
EP1406871A4 (en) 2005-01-26
CN1537113A (zh) 2004-10-13
SK16232003A3 (sk) 2004-12-01
NO20035538D0 (no) 2003-12-11
WO2002100828A3 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
US5922914A (en) Process to prepare tolterodine
US7956048B2 (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
JP7855657B2 (ja) フロイミダゾピリジン化合物、多形物質および塩の多形物質の合成方法
US6884888B2 (en) Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)
KR20220016955A (ko) 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
US20190218231A1 (en) Crystal Forms And Salt Forms Of 7h-Pyrrolo[2,3-D]Pyrimidine Compounds And Preparation Method Thereof
CN117897383A (zh) 乌洛地辛盐
WO2010126138A1 (ja) ３環性ベンゾピラン化合物の新規な結晶形態及びその製造方法
AU2002348641A1 (en) Process for the production of zaleplon
CA3108134C (en) Crystalline eltrombopag monoethanolamine salt form d
CN115968369B (zh) 作为pi3k抑制剂的化合物的制备方法及用于制备其的中间体化合物
WO2019064222A1 (en) CRYSTALLINE FORMS OF LENALIDOMIDE
JPH0662618B2 (ja) オクタヒドロピラゾロ［３，４−ｇキノリン類の製造
KR20170036288A (ko) 시타글립틴의 신규염 및 이의 제조방법
US20070004737A1 (en) Process of purifying tadalafil
CN104945272A (zh) N-[5-(3-二甲基氨基-丙烯酰基)-2-氟-苯基]-n-甲基-乙酰胺的制备方法

Legal Events

Date Code Title Description
A1OB Publication of a patent application
PNAN Change of the applicant name, address/residence

Owner name: TEVA GYOGYSZERGYAR RESZVENYTARSASAG, HU

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20050606

Year of fee payment: 4

OBST Application withdrawn